-
3m 10sPart 1 | Session 5 Albuminuria, eGFR Dip and Disease Severity & Empagliflozin
-
5m 27s
-
4m 16sPart 1 | Session 7 Treating Obesity in 2025 and Beyond
-
5m 36sPart 2 | Session 1 Highlights with Dr Johannes Stegbauer
-
1m 45sPart 2 | Session 2 Highlights with Dr Kywe Kywe Soe
-
3m 13s
-
2m 39sPart 1 | Session 2 Real-World Data for CV and Renal Outcomes in Diabetic Kidney Disease
-
2m 52s
ERA 2025 - Real-world outcomes show switching from treatment with steroidal mineralocorticoid receptor antagonists (sMRAs) to finerenone is a safe option in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).
Dr Beatriz Fernandez Fernandez (Hospital Universitario Fundación Jiménez Dïaz, Madrid, ES) joins us to discuss real-world outcomes from a study investigating the effect of switching from treatment with sMRAs to finerenone in patients with CKD and T2D across multiple centres in Madrid.
Findings showed that potassium levels significantly decreased in patients who switched from sMRAs to finerenone. Furthermore, albuminuria and eGFR levels in patents who switched treatments decrease at an equal level to patients on sMRAs.
Interview Questions:
1. What is the reasoning behind the study?
2. What was the study design, patient population and the key findings?
3. How should these findings impact clinical practice?
4. What further research is needed in this area?
Recorded on-site at ERA in Vienna, 2025.
Editors: Jordan Rance, Yazmin Sadik
Videographers: David Ben-Harosh, Tom Green
Support: This is an independent interview produced by Radcliffe CVRM.
Keep up-to-date with the late-breaking presentations from the European Renal Association's 62nd congress, taking place from 4th to 7th June 2025 in Vienna. With Expert Interviews focusing on the applicability of the latest data and Highlights summarising the key take-aways, our video collection has you covered.
More from this programme
Part 1
Expert Interviews
Part 2
Comments